Skip to main content
SpringerLink
Log in

Chemotherapy in Metastatic Urothelial Cancer

Current and Future Treatment Options

  • Review Article
  • Published:
American Journal of Cancer

Abstract

For more than a decade, the cisplatin plus doxorubicin and methotrexate plus vinblastine (MVAC) regimen has been the gold standard chemotherapy in bladder cancer, although the toxicity associated with this therapy has hampered its use in many older patients with metastatic disease. In recent years, new active agents have been identified, combinations of new agents with established drugs followed and results have become available on the combination of gemcitabine and cisplatin vs MVAC that have revealed an efficacy-toxicity profile in favor of the gemcitabine-cisplatin regimen. Other new doublet and triplet combinations, comprising new agents as well as incorporating one or two new agents into established regimens have demonstrated significant activity in phase II studies. However, there are no randomized data to show that any of these regimens improves patient survival as compared with either MVAC or cisplatin-gemcitabine. Advances in the understanding of the molecular biology of urothelial cancer will help to identify new biochemical targets for the development of novel therapeutic approaches to treat this cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification only and does not imply endorsement.

References

  1. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987; 60: 574–85

    Article  PubMed  CAS  Google Scholar 

  2. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (metho-trexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. JUrol 1985; 133: 403–7

    CAS  Google Scholar 

  3. Sternberg CN, Yagoda A, Scher HI, et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse. Cancer 1989; 64: 2448–58

    Article  PubMed  CAS  Google Scholar 

  4. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital Experience. JUrol 1989; 142: 289–92

    CAS  Google Scholar 

  5. Igawa M, Ohkuchi T, Ueki T, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol 1990; 144: 662–5

    PubMed  CAS  Google Scholar 

  6. Boutan-Laroze A, Mahjoubi M, Droz JP, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 1991; 27: 1690–4

    Article  PubMed  CAS  Google Scholar 

  7. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992; 10: 1066–73

    PubMed  Google Scholar 

  8. Logothetis CJ, Dexeus FH, Finn L, et al. Aprospective randomized trial comparing MVAC and CISC A chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050–5

    PubMed  CAS  Google Scholar 

  9. Geller NL, Sternberg CN, Penenberg D, et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991; 67: 1525–31

    Article  PubMed  CAS  Google Scholar 

  10. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17: 3173–81

    PubMed  CAS  Google Scholar 

  11. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564–9

    PubMed  CAS  Google Scholar 

  12. Connor JP, Olsson CA, Benson MC, et al. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of the urinary bladder: cause for concern. Urology 1989; 34: 353–6

    Article  PubMed  CAS  Google Scholar 

  13. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. NEngl JMed 1988; 318: 1414–22

    Article  CAS  Google Scholar 

  14. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recobinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150: 1131–4

    PubMed  CAS  Google Scholar 

  15. Loehrer PJ, Elson P, Dreicer R, et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1994; 12: 483–8

    PubMed  Google Scholar 

  16. Seidman AD, Scher HI, Gabrilove JL, et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. JClin Oncol 1993; 11: 408–14

    PubMed  CAS  Google Scholar 

  17. Scher HI, Geller NL, Curley T, et al. Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. J Clin Oncol 1993; 11: 400–7

    PubMed  CAS  Google Scholar 

  18. Logothetis CJ, Finn LD, Smith T, et al. Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 1995; 13: 2272–7

    PubMed  CAS  Google Scholar 

  19. Sternberg CN, de Mulder PHM, Schornagel J, et al. Randomized phase III trial in advanced urothelial tract tumors of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC. J Clin Oncol 2001; 19: 2638–46

    PubMed  CAS  Google Scholar 

  20. deWit R, Tesselaar M, Kok TC, et al. Randomized phase II trial of carboplatin and iproplatin in advanced urothelial cancer. Eur J Cancer 1991; 27: 1383–5

    Article  PubMed  Google Scholar 

  21. Bellmunt J, Albaneil J, Gallego O, et al. Carboplatin, Methotrexate, and Vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992; 70: 1974–9

    Article  PubMed  CAS  Google Scholar 

  22. Boccardo F, Pace M, Guarneri D, et al. Carboplatin, methotrexate and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer 1994; 73: 1932–6

    Article  PubMed  CAS  Google Scholar 

  23. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966–72

    Article  PubMed  CAS  Google Scholar 

  24. de Wit R, Kaye SB, Roberts JT, et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 1993; 67: 388–90

    Article  PubMed  Google Scholar 

  25. Khorsand M, Lange J, Feun L. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder [abstract 821]. Proc AmSoc Clin Oncol 1996; 15: 297

    Google Scholar 

  26. Roth BJ, Dreicer R, Einhorn LH, et al. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group [E1892]. J Clin Oncol 1994; 12: 2264–70

    PubMed  CAS  Google Scholar 

  27. Papamichael D, Gallagher CJ, Oliver RTD, et al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997; 75: 606–7

    Article  PubMed  CAS  Google Scholar 

  28. Broome CM, Hussain M, Gutheil J, et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer [abstract 1381]. Proc AmSoc Clin Oncol 2000; 19: 351

    Google Scholar 

  29. de Wit R, Kruit WHJ, Stoter G, et al. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. Br J Cancer 1998; 78: 1342–5

    Article  PubMed  Google Scholar 

  30. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853–7

    PubMed  CAS  Google Scholar 

  31. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182–4

    PubMed  CAS  Google Scholar 

  32. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 1997; 15: 3394–8

    PubMed  CAS  Google Scholar 

  33. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 1997; 15: 3441–5

    PubMed  CAS  Google Scholar 

  34. Lorusso V, Pollera CF, Antimi M, et al. Aphase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum: Italian Cooperative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208–12

    Article  PubMed  CAS  Google Scholar 

  35. Gebbia V, Testa A, Borsellino N, et al. Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter 1999; 150: 11–5

    PubMed  CAS  Google Scholar 

  36. Albers P, Siener R, Perabo FG, et al. Gemcitabine monotherapy as 2nd-line treatment in cisplatin refractory transitional cell carcinoma [abstract 1360]. Proc Am Soc Clin Oncol 2000; 19: 346a

    Google Scholar 

  37. Paz-Ares L, Tabernero J, Moyano A, et al. A phase II of the multi-targeted anti-folate, MTA (LY231514), in patients with advanced transitional cell carcinoma of the bladder [abstractl307]. Proc AmSoc Clin Oncol 1998; 17: 339a

    Google Scholar 

  38. Murphy BA, Johnson DR, Smith J, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer [abstract 617]. Proc Am Soc Clin Oncol 1996; 15: 245

    Google Scholar 

  39. Burch PA, Richardson RL, Cha SS, et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma [abstract 1266]. Proc Am Soc Clin Oncol 1999; 18: 329

    Google Scholar 

  40. Dreicer R, Manola J, Roth B, et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group (ECOG) study. J Clin Oncol 2000; 18: 1058–61

    PubMed  CAS  Google Scholar 

  41. Dimopoulos MA, Bakoyannis C, Georgoulias V, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 1999; 10: 1385–8

    Article  PubMed  CAS  Google Scholar 

  42. Sengeløv L, Kamby C, Lund B, et al. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998; 16: 3392–7

    PubMed  Google Scholar 

  43. del Muro G, Marcuello E, Guma R, et al. Phase II study of docetaxel (D) and cisplatin (CDDP) in advanced urothelial cancer: preliminary results [abstract 1356]. Proc Am Soc Clin Oncol 2000; 19: 345a

    Google Scholar 

  44. Pycha A, Grbovic M, Posch B, et al. Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract. Urology 1999; 53: 510–5

    Article  PubMed  CAS  Google Scholar 

  45. Droz JP, Mottel N, Prapotrich D, et al. Phase II study of taxol (Paclitaxel) and carboplatin in patients with advanced transitional-cell carcinoma of the urothelium: preliminary results [abstract 1219]. Proc Am Soc Clin Oncol 1998; 17: 316a

    Google Scholar 

  46. Bauer J, Stalder M, Roth A, et al. Phase II trial of paclitaxel (P) plus carboplatin (C ) in advanced urothelial tract cancer (UTC) [abstract 1255]. Proc Am Soc Clin Oncol 1998; 17: 326a

    Google Scholar 

  47. Vaughn DJ, Malkowicz SB, Zoltick B, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998; 16: 255–60

    PubMed  CAS  Google Scholar 

  48. Redman BG, Smith DC, Flaherty L, et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998; 16: 1844–8

    PubMed  CAS  Google Scholar 

  49. Small EJ, Lew D, Redman BG, et al. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000; 18: 2537–44

    PubMed  CAS  Google Scholar 

  50. Peters GJ, Bergman AM, Ruiz van Haperen VW, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22 Suppl. 11: 72–9

    Google Scholar 

  51. Van Moorsel CJ, Veerman G, Vermorken JB, et al. Mechanisms of synergism between gemcitabine and cisplatin. Source Adv Exp Med Biol 1998; 431: 581–5

    Article  Google Scholar 

  52. Von der Maase H, Andersen L, Crino L, et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann Oncol 1999; 10: 1461–5

    Article  PubMed  Google Scholar 

  53. Moore MJ, Winquist EW, Murray N, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999; 17: 2876–81

    PubMed  CAS  Google Scholar 

  54. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18: 1921–7

    PubMed  CAS  Google Scholar 

  55. Von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 17: 3068–77

    Google Scholar 

  56. Von der Maase H, Hansen SW, Liepa A, et al. Health care resourse use for patients with advanced bladder cancer treated with gemcitabine plus cisplatin (GC) versus MVAC in a phase III trial [abstract 327]. Ann Oncol 2000; 11 Suppl. 4: 74

    Google Scholar 

  57. Bellmunt J, Witde R, Albaneil J. Afeasibility study of carboplatin with fixed dose of gemcitabine in unfit patients with advanced bladder cancer. Eur J Cancer. In press

  58. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19: 1071–7

    PubMed  CAS  Google Scholar 

  59. Marini L, Sternberg CN, Sella A, et al. A new regimen of gemcitabine and paclitaxel in previously treated patients with advanced transitional cell carcinoma [abstract 1335]. Proc Am Soc Clin Oncol 1999; 18: 346a

    Google Scholar 

  60. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J. Clin Oncol 2001; 19: 3018–24

    PubMed  CAS  Google Scholar 

  61. Kaufman DS, Stadler WM, Carducci MA, et al. Gemcitabine and paclitaxel every two weeks: a multicenter phase II trial in locally advanced or metastatic urothelial cancer [abstract 1341]. Proc Am Soc Clin Oncol 2000; 19: 341a

    Google Scholar 

  62. Parameswaran R, Fisch MJ, Ansari RH, et al. A hoosier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell carcinoma of the bladder [abstract 798]. Proc Am Soc Clin Oncol 2001; 20: 200a

    Google Scholar 

  63. Bellmunt J, GuillemV, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18: 3247–55

    PubMed  CAS  Google Scholar 

  64. Hussain M, Vaishampayan U, Du W, et al. Combination carboplatin, paclitaxel and gemcitabine: is an active teatment for advanced urothelial carcinoma. J Clin Oncol 2001; 19: 2527–33

    PubMed  CAS  Google Scholar 

  65. Hovey EJ, Owen CE, Shelton EB, et al. Phase I/II study of docetaxel, gemcitabine, carboplatin in poor prognosis and previously treated patients with urothelial carcinoma [abstract 1376]. Proc AmSoc Clin Oncol 2000; 19: 350a

    Google Scholar 

  66. Bajorin DF, McCaffrey JA, Hiltonv S, et al. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel and cisplatin: a phase II trial. J Clin Oncol 1998; 16: 2722–7

    PubMed  CAS  Google Scholar 

  67. Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000; 88: 1671–8

    Article  PubMed  CAS  Google Scholar 

  68. Tu SM, Hossan E, Amato R, et al. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. JUrol 1995; 154: 1719–22

    CAS  Google Scholar 

  69. Edelman MJ, Meyers FJ, Miller TR, et al. Phase I/II study of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma: a well tolerated regimen with activity independent of p53 mutation. Urology 2000; 55: 521–5

    Article  PubMed  CAS  Google Scholar 

  70. Pectasides D, Visvikis A, Aspropotamitis A, et al. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer: phase II trial. Eur J Cancer 2000; 36: 74–9

    Article  PubMed  CAS  Google Scholar 

  71. Law LY, Lara PN, Meyers FJ, et al. Platinum free combination chemotherapy in locally advanced and metastatic transitional cell carcinoma: phase I/II trial of gemcitabine, paclitaxel, methotrexate [abstract 767]. Proc AmSoc Clin Oncol 2001; 20: 192a

    Google Scholar 

  72. Dodd PM, McCaffrey JA, Hilton S, et al. Phase I evaluation of sequential doxorubicin + gemcitabine then ifosfamide + paclitaxel + cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. J Clin Oncol 2000; 18: 840–6

    PubMed  CAS  Google Scholar 

  73. Maluf FC, Hilton S, Nanus M, et al. Sequential doxorubicin/gemcitabine and ifosfamide, paclitaxel and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium [abstract 1344]. Proc AmSoc Clin Oncol 2000; 19: 342a

    Google Scholar 

  74. Novick S, Higgins G, Hilton S, et al. Phase I/II sequential doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with transitional cell carcinoma and impaired renal function [abstract 1423]. Proc Am Soc Clin Oncol 2000; 19: 361a

    Google Scholar 

  75. Messing EM, Reznikoff CA. Normal and malignant urothelium: in vitro effects of epidermal growth factor. Cancer Res 1987; 47: 2230–6

    PubMed  CAS  Google Scholar 

  76. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985; I: 366–9

    Article  Google Scholar 

  77. Izawa JI, Slaton JW, Kedar D, et al. Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder. Oncol Rep 2001; 8: 9–15

    PubMed  CAS  Google Scholar 

  78. Ravery V, Grignon D, Angulo J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. UrolRes 1997; 25: 9–17

    CAS  Google Scholar 

  79. Chow NH, Chan SH, Tzai TS, et al. Expression profiles of erbb family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001; 7: 1957–62

    PubMed  CAS  Google Scholar 

  80. Rubin MS, Shin DM, Pasmatier M, et al. Monoclonal antibody IMC-C225, an anti-epidermal growth factor receptor, for patients with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens [abstract I860]. Proc AmSoc Clin Oncol 2000; 19: 474a

    Google Scholar 

  81. Ferry D, Hammond L, Ranson M, et al. Intermittent oral ZD 1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor, shows evidence of good tolerability and activity: finals results from a phase I study [abstract 5E]. Proc Am Soc Clin Oncol 2000; 19: 3a

    Google Scholar 

  82. Shack S. Overview of the Traztuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin Oncol 1999; 26 Suppl. 12: 71–7

    Google Scholar 

  83. Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol 1999; 26Suppl. 12: 71–7

    Google Scholar 

  84. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6: 4885–92

    PubMed  CAS  Google Scholar 

  85. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000; 6: 4874–84

    PubMed  CAS  Google Scholar 

  86. Miller VA, Johnson D, Heelan RT, et al. A pilot trial demonstrates the safety of zdl839 ( ;iressa ;), an oral epidermal growth factor receptor tyrosine kinase inhibitor (egfr-tki), in combination with carboplatin (c) and paclitaxel (p) in previously untreated advanced non-small cell lung cancer (nsclc) [abstract 1301]. Proc Am Soc Clin Oncol 2001; 20: 326a

    Google Scholar 

  87. Jimenez RE, Hussain M, Bianco Jr FJ, et al. Her-2/neu Overexpression in muscleinvasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001; 7: 2440–7

    PubMed  CAS  Google Scholar 

  88. Estrada CR, CooganCL, Kapur S, et al. Her-2/neu receptor protein over-expression in grade I, II and III bladder transitional cell carcinoma [abstract 794]. Proc Am Soc Clin Oncol 2001; 20: 199a

    Google Scholar 

  89. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92

    Article  PubMed  CAS  Google Scholar 

  90. Winquist E, Moore MJ, Chi K, et al. NCIC CTG IND 128: a phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract failing prior chemotherapy [abstract785]. Proc AmSoc Clin Oncol 2001; 20: 197a

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, PO Box 5201, Rotterdam, 3008 AE, The Netherlands

    Ronald de Wit

  2. Hospital General Universitari Vall d’Hebron, Barcelona, Spain

    Joaquim Bellmunt

Authors
  1. Ronald de Wit
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joaquim Bellmunt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ronald de Wit.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Wit, R., Bellmunt, J. Chemotherapy in Metastatic Urothelial Cancer. Am J Cancer 1, 23–31 (2002). https://doi.org/10.2165/00024669-200201010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024669-200201010-00004

Keywords

Search

Navigation